Smaller Drug Makers Chugai, Mitsubishi Tanabe Less Exposed To Bad Economy Than Big
This article was originally published in PharmAsia News
Executive Summary
Smaller Japanese drug makers have done a better job surviving the global economic crisis than have their larger competitors. Among the second-tier Japanese pharmaceuticals doing well in a troubled period are Chugai Pharmaceutical, Mitsubishi Tanabe Pharma and Tsumura, primarily because they are less exposed to economic conditions in other nations such as the United States. The small and midsize firms also have spent less than the larger ones on acquisitions in recent years that made them more exposed to a market downturn. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.